Michigan Institute of Urology is one of the longest-standing and largest urology practices in the state of Michigan, utilizing the latest, clinically proven techniques to diagnose and treat a wide variety of urologic disorders in men, women, and children. Our specialists have been recruited from the most sophisticated university centers to serve our patients throughout Metro Detroit.
What to know when considering an ancillary service in a urology practice
February 6th 2024"At MIU, we host many ancillary services, including complete ultrasound services, UroCuff, urodynamics, PTNS [percutaneous tibial nerve stimulation], full laboratory and pathology services, Xofigo [radium-223]," says Jason M. Hafron, MD.
ECLIPSE trial evaluating PSMA agent for metastatic castration-resistant prostate cancer
August 30th 2023"The purpose of the study is to compare the safety and efficacy of lutetium PSMA I&T vs standard of care hormone therapy in patients with metastatic castration-resistant prostate cancer," says Jason M. Hafron, MD.
Dr. Hafron discusses the use of oral Relugolix in prostate cancer
April 29th 2023"What we noticed is that even though it's not in the NCCN guidelines, a lot of urologists are using oral Relugolix in combination with other prostate cancer medications in similar numbers to the injectables," says Jason M. Hafron, MD.
Tips for optimizing an advanced prostate cancer clinic
November 11th 2022In an interview during the 2022 LUGPA Annual Meeting, Jason M. Hafron, MD, shared advice on optimizing advanced prostate cancer clinics, recapped the biggest advances in urologic cancer treatment in 2022, and discussed how Jelmyto treatment for UTUC has evolved over time.
Dr. Lutz discusses testicular cancer awareness
May 6th 2022“While we have these young men in our offices, we need to try and engage them for all of the necessary screening opportunities that will improve the quality of their lives moving forward,” says Michael Lutz, MD, in this podcast episode.
Dr. Hafron on LUGPA 2021 and the rapidly evolving prostate and bladder cancer treatment landscapes
November 22nd 2021In this interview, Jason M. Hafron, MD, discusses the “buzz” surrounding the meeting and touches on clinical topics including germline and somatic testing, PARP inhibitors, and mitomycin-containing reverse thermal gel (Jelmyto).
Dr. Hafron on PARP inhibitors in prostate cancer
November 16th 2021“I think as our understanding of mutations [and] our understanding the PARP inhibitors [grows], if the data pans out, we'll be using these earlier and earlier in patients, which I think we'll [will allow us to] see probably more benefit,” says Jason M. Hafron, MD.
Upper tract transitional cell carcinoma: Diagnostic and therapeutic considerations
Determining grade of disease is important, as nephron-sparing approaches may be feasible.